Arbutus Biopharma (ABUS) Misses Q3 EPS by 1c

Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $530 thousand versus the consensus estimate of $1.39 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance
• Boeing wins $13.4 billion contract modification from US military